In matched groups of human patients from the National COVID Cohort Collaborative, CBD (100 mg/ml oral solution per medical records) had a significant negative association with positive SARS-CoV-2 tests. CBD inhibits SARS-CoV-2 replication in part by up-regulating the host IRE1α ribonuclease endoplasmic reticulum (ER) stress response and interferon signaling pathways. CBD acts after viral entry, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2 replication in lung epithelial cells. Here, we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and ongoing coronavirus disease 2019 (COVID-19) pandemic underscores the need for new treatments. Meltzer, Glenn Randall, and Marsha Rich Rosner +30 authors +28 authors +23 authors fewer Authors Info & Affiliations Palmer, The National COVID Cohort Collaborative Consortium, David O. Anderson, James Michael Millis, Bryan C. Gabbard, Shao-Nong Chen, Takashi Ohtsuki, , John Brent Friesen, Nir Drayman, Adil Mohamed, Christopher Dann, Diane Silva, Lydia Robinson-Mailman, Andrea Valdespino, Letícia Stock, Eva Suárez, Krysten A. Best, , Haley Gula, Divyasha Saxena, Jon D. Long Chi Nguyen, Dongbo Yang, , Vlad Nicolaescu, Thomas J.

Cbd copy bad disk serial number